Heartport Stock Up 97% In September On Acquisition Interest, New Products
This article was originally published in The Gray Sheet
Continued strong interest in minimally invasive surgery by cardiac surgeons, acquisition of competitors in the sector, a new CEO and several recent product introductions appeared to help stimulate a 97.3% gain in Heartport stock in September. The issue gained 2-1/4 points to close the month at 4-9/16.
You may also be interested in...
ArthroCare anticipates pursuing additional spinal applications within the next year for its Coblation-based surgical tools following the firm's recent entry into the European spine surgery market.
Continued strong demand for Candela's flagship aesthetic lasers, including the GentleLase for hair removal and ScleroPlus for vascular lesions, coupled with the release of strong third-quarter financial results ahead of some analysts' expectations, drove the firm's stock price in April. The issue gained 9-3/4 points to close at 18-3/4 for the month, an increase of 108.3%.
Law firm of Barrack, Rodos & Bacine adds to a growing list of class action suits maintaining that the company's officers issued "false and misleading" financial results from Jan. 1996 through Dec. 1998. The suit, filed in San Francisco federal court, was sparked by ADAC's Dec. 29 announcement that financial results for 1996-98 would be restated and that the adjustments would "have a material adverse impact" on fiscal 1996 and 1997 results